Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Li

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Psychopharmacology|December 21, 2012
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/MavoglurantAndreea S Pop, Josien Levenga, Celine E F de Esch, et al.
Arthritis and Rheumatism|April 3, 2008
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexateJoel M Kremer, Harry K Genant, Larry W Moreland, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2022
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapyAnna Minchom, Santiago Viteri, Lyudmila Bazhenova, et al.
Annals of the Rheumatic Diseases|September 7, 2011
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialJoel M Kremer, Anthony S Russell, Paul Emery, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2012
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest groupEric Faulkner, Lieven Annemans, Lou Garrison, et al.
Lung Cancer (Amsterdam, Netherlands)|November 24, 2021
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutationsLyudmila Bazhenova, Anna Minchom, Santiago Viteri, et al.
Arthritis and Rheumatism|July 30, 2005
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trialJoel M Kremer, Maxime Dougados, Paul Emery, et al.
The Journal of Rheumatology|September 10, 2009
Assessing quality of sleep in patients with rheumatoid arthritisGeorge A Wells, Tracy Li, John R Kirwan, et al.
Future Oncology (London, England)|October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancerTae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Psychopharmacology|December 21, 2012
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/MavoglurantAndreea S Pop, Josien Levenga, Celine E F de Esch, et al.
Arthritis and Rheumatism|April 3, 2008
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexateJoel M Kremer, Harry K Genant, Larry W Moreland, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2022
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapyAnna Minchom, Santiago Viteri, Lyudmila Bazhenova, et al.
Annals of the Rheumatic Diseases|September 7, 2011
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialJoel M Kremer, Anthony S Russell, Paul Emery, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2012
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest groupEric Faulkner, Lieven Annemans, Lou Garrison, et al.
Lung Cancer (Amsterdam, Netherlands)|November 24, 2021
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutationsLyudmila Bazhenova, Anna Minchom, Santiago Viteri, et al.
Arthritis and Rheumatism|July 30, 2005
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trialJoel M Kremer, Maxime Dougados, Paul Emery, et al.
The Journal of Rheumatology|September 10, 2009
Assessing quality of sleep in patients with rheumatoid arthritisGeorge A Wells, Tracy Li, John R Kirwan, et al.
Future Oncology (London, England)|October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancerTae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Pageof 6